Retrospective Study
Copyright ©The Author(s) 2015.
World J Hepatol. Sep 8, 2015; 7(19): 2220-2228
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2220
Figure 2
Figure 2 Cumulative hepatocellular carcinoma incidence after interferon therapy. Cumulative hepatocellular carcinoma incidence after interferon therapy was compared in groups of patients classified by the outcome of interferon therapy using the Kaplan-Meier method. HCC: Hepatocellular carcinoma; SVR: Sustained virological response; NVR: Partial or null virological response.

  • Citation: Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, Hashimoto N, Sakaguchi K, Sakata T, Ando M, Makino Y, Matsumura S, Takayama H, Seki H, Nanba S, Moritou Y, Yasunaka T, Ohnishi H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol 2015; 7(19): 2220-2228
  • URL: https://www.wjgnet.com/1948-5182/full/v7/i19/2220.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v7.i19.2220